Literature DB >> 17036395

Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease.

Anatol Panasiuk1, Janusz Dzieciol, Bozena Panasiuk, Danuta Prokopowicz.   

Abstract

AIM: To analyze the protein expression essential for apoptosis in liver steatosis.
METHODS: The expression of proapoptotic proteins p53, Bax, and antiapoptotic Bcl-2 in hepatocytes with steatosis (SH) and without steatosis (NSH) was evaluated in 84 patients at various stages of non-alcoholic fatty liver disease (NAFLD).
RESULTS: Immunohistochemical staining of liver tissue showed the activation of p53 protein in SH and NSH with increased liver steatosis, diminished Bcl-2 and slightly decreased Bax protein. Positive correlation was found between the stage of liver steatosis with p53 expression in SH (r = 0.54, P < 0.01) and NSH (r = 0.49, P < 0.01). The antiapoptotic protein Bcl-2 was diminished together with the advancement of liver steatosis, especially in non-steatosed hepatocytes (r = 0.43, P < 001).
CONCLUSION: Apoptosis is one of the most important mechanisms leading to hepatocyte elimination in NAFLD. The intensification of inflammation in NAFLD induces proapoptotic protein p53 with the inhibition of antiapoptotic Bcl-2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17036395      PMCID: PMC4088117          DOI: 10.3748/wjg.v12.i38.6198

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  21 in total

1.  Non-alcoholic steatohepatitis: another disease of affluence.

Authors:  O James; C Day
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

2.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

3.  Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases.

Authors:  Shuichi Seki; Takuya Kitada; Hiroki Sakaguchi
Journal:  Hepatol Res       Date:  2005-09-29       Impact factor: 4.288

4.  Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling.

Authors:  Jörn M Schattenberg; Yongjun Wang; Rajat Singh; Raina M Rigoli; Mark J Czaja
Journal:  J Biol Chem       Date:  2005-01-04       Impact factor: 5.157

5.  Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice.

Authors:  N Tsuboyama-Kasaoka; M Takahashi; K Tanemura; H J Kim; T Tange; H Okuyama; M Kasai; S Ikemoto; O Ezaki
Journal:  Diabetes       Date:  2000-09       Impact factor: 9.461

6.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

7.  Saturated free fatty acid, palmitic acid, induces apoptosis in fetal hepatocytes in culture.

Authors:  Jun Ji; Li Zhang; Ping Wang; Yi-Ming Mu; Xiao-Yu Zhu; Yuan-Yuan Wu; Huan Yu; Bin Zhang; Shu-Min Chen; Xi-Zuo Sun
Journal:  Exp Toxicol Pathol       Date:  2005-04

Review 8.  Pancreatic beta-cell growth and survival--a role in obesity-linked type 2 diabetes?

Authors:  Melissa K Lingohr; Roland Buettner; Christopher J Rhodes
Journal:  Trends Mol Med       Date:  2002-08       Impact factor: 11.951

9.  Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway.

Authors:  Ariel E Feldstein; Nathan W Werneburg; Ali Canbay; Maria Eugenia Guicciardi; Steven F Bronk; Robert Rydzewski; Laurence J Burgart; Gregory J Gores
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

10.  Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated.

Authors:  Roberto Lupi; Francesco Dotta; Lorella Marselli; Silvia Del Guerra; Matilde Masini; Carmela Santangelo; Giovanni Patané; Ugo Boggi; Salvatore Piro; Marcello Anello; Ettore Bergamini; Franco Mosca; Umberto Di Mario; Stefano Del Prato; Piero Marchetti
Journal:  Diabetes       Date:  2002-05       Impact factor: 9.461

View more
  45 in total

1.  The p53 Codon 72 Polymorphism Modifies the Cellular Response to Inflammatory Challenge in the Liver.

Authors:  Julia I-Ju Leu; Maureen E Murphy; Donna L George
Journal:  J Liver       Date:  2013

2.  Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD/NASH.

Authors:  Xiaoya Li; Jing Wang; Xue Gong; Meiling Zhang; Shuangshuang Kang; Bing Shu; Zuzhuang Wei; Zhi-Shu Huang; Ding Li
Journal:  Nucleic Acids Res       Date:  2020-09-04       Impact factor: 16.971

Review 3.  From bed to bench: which attitude towards the laboratory liver tests should health care practitioners strike?

Authors:  Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2007-10-07       Impact factor: 5.742

Review 4.  Calcium signaling in the liver.

Authors:  Maria Jimena Amaya; Michael H Nathanson
Journal:  Compr Physiol       Date:  2013-01       Impact factor: 9.090

Review 5.  Targeting inflammation in diabetes: Newer therapeutic options.

Authors:  Neeraj Kumar Agrawal; Saket Kant
Journal:  World J Diabetes       Date:  2014-10-15

6.  Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease.

Authors:  Giovanni Tarantino; Francesco Scopacasa; Annamaria Colao; Domenico Capone; Marianna Tarantino; Ernesto Grimaldi; Silvia Savastano
Journal:  World J Gastroenterol       Date:  2011-12-28       Impact factor: 5.742

Review 7.  p53 in liver pathologies-taking the good with the bad.

Authors:  Meital Charni; Noa Rivlin; Alina Molchadsky; Ronit Aloni-Grinstein; Varda Rotter
Journal:  J Mol Med (Berl)       Date:  2014-11-19       Impact factor: 4.599

8.  Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice.

Authors:  Takahiro Kodama; Tetsuo Takehara; Hayato Hikita; Satoshi Shimizu; Minoru Shigekawa; Hinako Tsunematsu; Wei Li; Takuya Miyagi; Atsushi Hosui; Tomohide Tatsumi; Hisashi Ishida; Tatsuya Kanto; Naoki Hiramatsu; Satoshi Kubota; Masaharu Takigawa; Yoshito Tomimaru; Akira Tomokuni; Hiroaki Nagano; Yuichiro Doki; Masaki Mori; Norio Hayashi
Journal:  J Clin Invest       Date:  2011-07-11       Impact factor: 14.808

9.  Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease.

Authors:  Zoltan Derdak; Kristine A Villegas; Ragheb Harb; Annie M Wu; Aryanna Sousa; Jack R Wands
Journal:  J Hepatol       Date:  2012-12-02       Impact factor: 25.083

Review 10.  The role of the p53 tumor suppressor in metabolism and diabetes.

Authors:  Che-Pei Kung; Maureen E Murphy
Journal:  J Endocrinol       Date:  2016-09-09       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.